DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapyCynthia Bernier, Anne Roulston, Paul Savage et al.|Anti-Cancer Drugs|2018Cited by 22